Jubilant Pharmova stock gains 6.45% in an overall weak market; here's why
Jubilant Pharmova's share price surged 6.45% after its Radiopharma business received ANDA approval for Technetium Sulfur Colloid Injection.
Source: livemint.com
Stay updated with breaking news from Sulfur Collid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jubilant Pharmova's share price surged 6.45% after its Radiopharma business received ANDA approval for Technetium Sulfur Colloid Injection.
For this approval, Jubilant is eligible for 180 days of exclusivity through the ‘Competitive Generic Therapy designation from the US FDA.